Lyell Immunopharma Inc, a Pharmaceuticals company based in the USA, has a risk rating score of 25.1, categorizing it as a medium-risk investment. Specializing in cell therapy, Lyell Immunopharma focuses on developing innovative treatments for solid tumors using ESG-approved ex vivo genetic and epigenetic T-cell reprogramming technologies. With a product pipeline featuring LYL797, LYL119, LYL845, and more, Lyell Immunopharma aims to revolutionize cancer treatment through sustainable and cutting-edge approaches.